We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

CARDIALYSIS and Sticares InterACT Announce Strategic Collaboration

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute
Cardialysis and Sticares InterACT, both Contract Research Organizations (CROs) headquartered in The Netherlands, announced that they have entered into a strategic collaboration to provide drug development consulting services in the field of cardiovascular and metabolic medicine. Both organizations have substantial experience and success in the execution of clinical research projects for pharmaceutical, biotechnology and medical device companies.

Cardialysis and Sticares InterACT have been independently active for more than 25 years conducting high-quality cardiovascular and metabolic focused clinical research. Each of the two companies has unique and complementary service offerings and both share a common history with roots planted firmly in academia. Strong ties to cardiologists, physicians, research scientists, and key opinion leaders allow for easy access to leading drug development knowledge. As a result of their academic origins, Sticares InterACT and Cardialysis are able to offer expert drug development services well beyond that of ordinary CROs.

“The synergy resulting from this collaboration offers sponsors concrete and exceptional advantages”, states Karen Keukelaar, COO of Sticares InterACT. “Cardialysis has its strengths in core laboratory techniques and web-based clinical event adjudication, statistics, data management and clinical trial management whereas Sticares InterACT excels in clinical project management, site management in 26 countries with a strong presence in Eastern Europe, medical monitoring, event management and pharmacovigilance. So, we are very complementary”.

Driek Vergouwen, CEO of Cardialysis, adds: “Joining strengths means that our organizations together can offer complete clinical research services to our customers that combine scientific know-how with broad medical experience and outstanding international execution. Our mutual specialization in cardiology and metabolic diseases for many years makes us the preferred international partner for companies in need of high quality clinical studies in these fields.”

The collaboration between Cardialysis and Sticares InterACT ensures high quality clinical research services, accelerated subject recruitment, therapeutic competence and medical expertise for current and future clients. Cardialysis and Sticares InterACT together offer a complete spectrum of services from pre-clinical consulting to planning, managing, executing and reporting phase II-IV clinical research programs.